A sequentially triggered DNA nanocapsule for targeted drug delivery based on pH-responsive i-motif and tumor cell-specific aptamer

Yuan, Baoyin; Xi, Yanan; Qi, Cuihua; Zhao, Ming; Zhu, Xiaoyan; Tang, Jinlu

doi:10.3389/fbioe.2022.965337

Cited by 3 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The aptamer DNA-cyclodextrin makes the system freely slide along the polymer PEG chain and the assembly of drugs and the i-motif DNA can respond to pH change to release drugs under intracellular acidic conditions, enhancing cellular uptake and healing efficacy ( Jang et al, 2017 ). A DNA nanocapsule with an acidic pH-responsive i-motif DNA and a tumor cell-specific aptamer is first triggered by an acidic pH and then targets cells via the specific aptamer recognition and releases the carried drug doxorubicin, successfully providing selective cytotoxicity to cancer cells ( Yuan et al, 2022 ). Similarly, a nanocarrier based on bovine serum albumin and DNA including a pH-responsive i-motif and a cancer cell-targeted guanine-quadruplex-structured aptamer also showed accurate targeting and efficient therapeutic effect on cancer cells ( Yu et al, 2021 ).…”

Section: Applications In Precision Medicinementioning

confidence: 99%

Emerging roles of i-motif in gene expression and disease treatment

et al. 2023

View full text Add to dashboard Cite

As non-canonical nucleic acid secondary structures consisting of cytosine-rich nucleic acids, i-motifs can form under certain conditions. Several i-motif sequences have been identified in the human genome and play important roles in biological regulatory functions. Due to their physicochemical properties, these i-motif structures have attracted attention and are new targets for drug development. Herein, we reviewed the characteristics and mechanisms of i-motifs located in gene promoters (including c-myc, Bcl-2, VEGF, and telomeres), summarized various small molecule ligands that interact with them, and the possible binding modes between ligands and i-motifs, and described their effects on gene expression. Furthermore, we discussed diseases closely associated with i-motifs. Among these, cancer is closely associated with i-motifs since i-motifs can form in some regions of most oncogenes. Finally, we introduced recent advances in the applications of i-motifs in multiple areas.

show abstract

Section: Applications In Precision Medicinementioning

confidence: 99%

Emerging roles of i-motif in gene expression and disease treatment

et al. 2023

View full text Add to dashboard Cite

show abstract

Functionalities of pH-responsive DNA nanostructures in tumor-targeted strategies

Wen,

Wang

2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Development of Bivalent Aptamer-DNA Carrier-Doxorubicin Conjugates for Targeted Killing of Esophageal Squamous Cell Carcinoma Cells

Zhang,

Yin,

Niu

et al. 2024

IJMS

View full text Add to dashboard Cite

Esophageal cancer ranks the seventh in cancer incidence and the sixth in cancer death. Esophageal squamous cell carcinoma (ESCC) accounts for approximately 90% of the total cases of esophageal cancer. Chemotherapy is the most effective drug-based method for treatment of esophageal cancer. However, severe side effects of traditional chemotherapy limit its treatment efficacy. Targeted chemotherapy can deliver chemotherapeutic drugs to cancer cells and specifically kill these cells with reduced side effects. In the work, the bivalent aptamer-DNA carrier (BAD) was designed by using an ESCC cell-specific aptamer as the recognition molecule and a GC base-rich DNA sequence as the drug carrier. With doxorubicin (Dox) as chemotherapeutic drugs, the bivalent aptamer-DNA-Dox conjugate (BADD) was constructed for targeted killing of ESCC cells. Firstly, the truncated A2(35) aptamer with a retained binding ability was obtained through optimization of an intact A2(80) aptamer and was used to fuse with DNA carrier sequences for constructing the BAD through simple DNA hybridization. The results of gel electrophoresis and flow cytometry analysis showed that the BAD was successfully constructed and had a stronger binding affinity than monovalent A2(35). Then, the BAD was loaded with Dox drugs to construct the BADD through noncovalent intercalation. The results of fluorescence spectra and flow cytometry assays showed that the BADD was successfully constructed and can bind to target cells strongly. Confocal imaging further displayed that the BADD can be specifically internalized into target cells and release Dox. The results of CCK-8 assays, Calcein AM/PI staining, and wound healing assays demonstrated that the BADD can specifically kill target cells, but not control cells. Our results demonstrate that the developed BADD can specifically deliver doxorubicin to target ESCC cells and selectively kill these cells, offering a potentially effective strategy for targeted chemotherapy of ESCC.

show abstract

A sequentially triggered DNA nanocapsule for targeted drug delivery based on pH-responsive i-motif and tumor cell-specific aptamer

Cited by 3 publications

References 39 publications

Emerging roles of i-motif in gene expression and disease treatment

Emerging roles of i-motif in gene expression and disease treatment

Functionalities of pH-responsive DNA nanostructures in tumor-targeted strategies

Development of Bivalent Aptamer-DNA Carrier-Doxorubicin Conjugates for Targeted Killing of Esophageal Squamous Cell Carcinoma Cells

Contact Info

Product

Resources

About